UCB (OTCMKTS:UCBJY) Sees Strong Trading Volume - Time to Buy?

Key Points

• UCB saw trading volume surge to 84,999 shares on Wednesday (a 150% increase from 33,979), with the stock last trading at $156.2350 versus a prior close of $154.28.
• Wolfe Research upgraded UCB to a strong-buy on Feb. 23; overall two analysts rate it Strong Buy and one rates it Hold, giving the stock a MarketBeat average rating of Buy.
• The shares are trading above both the 50-day ($152.71) and 200-day ($144.45) moving averages, and UCB is a Belgium-based biopharma focused on neurology and immunology with marketed drugs such as CIMZIA, VIMPAT and NEUPRO.

UCB SA (OTCMKTS:UCBJY - Get Free Report) shares saw an uptick in trading volume on Wednesday . 84,999 shares were traded during trading, an increase of 150% from the previous session's volume of 33,979 shares.The stock last traded at $156.2350 and had previously closed at $154.28.

Analyst Ratings Changes

Separately, Wolfe Research upgraded shares of UCB to a "strong-buy" rating in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy".

UCB Price Performance

The stock has a 50 day moving average of $152.71 and a 200 day moving average of $144.45.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson's disease, rheumatoid arthritis and Crohn's disease.

The company's commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson's disease and restless legs syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.